tiprankstipranks
Resmed (CH:RME)
:RME
Switzerland Market
RME
Resmed
RESEARCH TOOLSreports

Resmed (RME) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

RME Analyst Ratings

Moderate Buy
15Ratings
Moderate Buy
4 Buy
11 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Resmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RME Stock 12 Month Forecast

Average Price Target

CHF192.05
▲(20.79% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is CHF192.05 with a high forecast of CHF257.68 and a low forecast of CHF171.52. The average price target represents a 20.79% change from the last price of CHF159.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"157":"CHF157","258":"CHF258","182.25":"CHF182.3","207.5":"CHF207.5","232.75":"CHF232.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":257.6784128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF257.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":192.05094204,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF192.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":171.51719352,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF171.52</span>\n  </div></div>","useHTML":true}}],"tickPositions":[157,182.25,207.5,232.75,258],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,158.472,166.10326252307692,173.73452504615386,181.36578756923078,188.9970500923077,196.62831261538463,204.25957513846154,211.89083766153846,219.5221001846154,227.1533627076923,234.78462523076922,242.41588775384616,250.04715027692308,{"y":257.6784128,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,158.472,161.05499554153846,163.63799108307694,166.2209866246154,168.80398216615384,171.38697770769232,173.96997324923078,176.55296879076923,179.1359643323077,181.71895987384616,184.3019554153846,186.8849509569231,189.46794649846154,{"y":192.05094204,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,158.472,159.47547642461538,160.47895284923078,161.48242927384615,162.48590569846155,163.48938212307692,164.49285854769232,165.4963349723077,166.4998113969231,167.50328782153846,168.50676424615386,169.51024067076924,170.5137170953846,{"y":171.51719352,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":158.472,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.472,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF257.68Average Price TargetCHF192.05Lowest Price TargetCHF171.52
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Rothschild & Co Redburn Analyst forecast on CH:RME
Jackson Philips
Rothschild & Co Redburn
Not Ranked
Rothschild & Co Redburn
CHF185.21
Hold
16.48%
Upside
Initiated
08/19/26
ResMed initiated with a Neutral at Rothschild & Co RedburnResMed initiated with a Neutral at Rothschild & Co Redburn
Mizuho Securities Analyst forecast on CH:RME
Anthony Petrone
Mizuho Securities
Mizuho Securities
CHF177.15→CHF189.23
Buy
19.01%
Upside
Reiterated
08/11/26
Mizuho Securities Remains a Buy on Resmed (RMD)
Oppenheimer Analyst forecast on CH:RME
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
―
Hold
―
Assigned
08/07/26
Oppenheimer Issues a Hold Rating on Resmed (RMD)
Piper Sandler Analyst forecast on CH:RME
Adam Maeder
Piper Sandler
Piper Sandler
CHF181.18
Hold
13.95%
Upside
Reiterated
08/07/26
Piper Sandler Sticks to Its Hold Rating for Resmed (RMD)
Needham Analyst forecast on CH:RME
Michael Matson
Needham
Needham
―
Hold
―
Reiterated
08/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed (NYSE: RMD) and High Tide (NASDAQ: HITI)
Robert W. Baird Analyst forecast on CH:RME
David Rescott
Robert W. Baird
Robert W. Baird
CHF174.74→CHF171.52
Hold
7.87%
Upside
Reiterated
08/07/26
ResMed price target lowered to $213 from $217 at BairdResMed price target lowered to $213 from $217 at Baird
KeyBanc Analyst forecast on CH:RME
Brett Fishbin
KeyBanc
KeyBanc
CHF209.36→CHF205.34
Buy
29.14%
Upside
Reiterated
08/07/26
Analysts Conflicted on These Healthcare Names: Astrana Health (NASDAQ: ASTH), Resmed (NYSE: RMD) and Definium Therapeutics (NASDAQ: DFTX)
RBC Capital Analyst forecast on CH:RME
Craig Wong-Pan
RBC Capital
RBC Capital
CHF188.43→CHF196.48
Hold
23.57%
Upside
Reiterated
08/07/26
RBC Capital Sticks to Their Hold Rating for Resmed (RMD)
Wells Fargo Analyst forecast on CH:RME
Nathan Treybeck
Wells Fargo
Wells Fargo
CHF181.18→CHF173.13
Hold
8.89%
Upside
Assigned
08/07/26
Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)
William Blair Analyst forecast on CH:RME
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
08/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)
Bank of America Securities Analyst forecast on CH:RME
Lyanne Harrison
Bank of America Securities
Bank of America Securities
CHF257.68
Buy
62.06%
Upside
Reiterated
07/29/26
Bank of America Securities Keeps Their Buy Rating on Resmed (RMD)
Morgan Stanley Analyst forecast on CH:RME
David Bailey
Morgan Stanley
Morgan Stanley
CHF185.21
Hold
16.48%
Upside
Reiterated
07/13/26
Resmed Maintained at Hold as Astral Ventilator Safety Notice Clouds Outlook; $230 Price Target Unchanged
Jefferies Analyst forecast on CH:RME
Matthew Taylor
Jefferies
Jefferies
CHF181.18
Hold
13.95%
Upside
Reiterated
07/10/26
Jefferies Issues a Hold Rating on Resmed (RMD)
Citi Analyst forecast on CH:RME
Laura Sutcliffe
Citi
Citi
CHF217.42→CHF189.23
Hold
19.01%
Upside
Downgraded
07/10/26
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD) and Eli Lilly & Co (NYSE: LLY)
Stifel Nicolaus Analyst forecast on CH:RME
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
CHF189.23
Hold
19.01%
Upside
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Meiragtx Holdings (NASDAQ: MGTX) and Resmed (NYSE: RMD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Rothschild & Co Redburn Analyst forecast on CH:RME
Jackson Philips
Rothschild & Co Redburn
Not Ranked
Rothschild & Co Redburn
CHF185.21
Hold
16.48%
Upside
Initiated
08/19/26
ResMed initiated with a Neutral at Rothschild & Co RedburnResMed initiated with a Neutral at Rothschild & Co Redburn
Mizuho Securities Analyst forecast on CH:RME
Anthony Petrone
Mizuho Securities
Mizuho Securities
CHF177.15→CHF189.23
Buy
19.01%
Upside
Reiterated
08/11/26
Mizuho Securities Remains a Buy on Resmed (RMD)
Oppenheimer Analyst forecast on CH:RME
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
―
Hold
―
Assigned
08/07/26
Oppenheimer Issues a Hold Rating on Resmed (RMD)
Piper Sandler Analyst forecast on CH:RME
Adam Maeder
Piper Sandler
Piper Sandler
CHF181.18
Hold
13.95%
Upside
Reiterated
08/07/26
Piper Sandler Sticks to Its Hold Rating for Resmed (RMD)
Needham Analyst forecast on CH:RME
Michael Matson
Needham
Needham
―
Hold
―
Reiterated
08/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed (NYSE: RMD) and High Tide (NASDAQ: HITI)
Robert W. Baird Analyst forecast on CH:RME
David Rescott
Robert W. Baird
Robert W. Baird
CHF174.74→CHF171.52
Hold
7.87%
Upside
Reiterated
08/07/26
ResMed price target lowered to $213 from $217 at BairdResMed price target lowered to $213 from $217 at Baird
KeyBanc Analyst forecast on CH:RME
Brett Fishbin
KeyBanc
KeyBanc
CHF209.36→CHF205.34
Buy
29.14%
Upside
Reiterated
08/07/26
Analysts Conflicted on These Healthcare Names: Astrana Health (NASDAQ: ASTH), Resmed (NYSE: RMD) and Definium Therapeutics (NASDAQ: DFTX)
RBC Capital Analyst forecast on CH:RME
Craig Wong-Pan
RBC Capital
RBC Capital
CHF188.43→CHF196.48
Hold
23.57%
Upside
Reiterated
08/07/26
RBC Capital Sticks to Their Hold Rating for Resmed (RMD)
Wells Fargo Analyst forecast on CH:RME
Nathan Treybeck
Wells Fargo
Wells Fargo
CHF181.18→CHF173.13
Hold
8.89%
Upside
Assigned
08/07/26
Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)
William Blair Analyst forecast on CH:RME
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
08/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)
Bank of America Securities Analyst forecast on CH:RME
Lyanne Harrison
Bank of America Securities
Bank of America Securities
CHF257.68
Buy
62.06%
Upside
Reiterated
07/29/26
Bank of America Securities Keeps Their Buy Rating on Resmed (RMD)
Morgan Stanley Analyst forecast on CH:RME
David Bailey
Morgan Stanley
Morgan Stanley
CHF185.21
Hold
16.48%
Upside
Reiterated
07/13/26
Resmed Maintained at Hold as Astral Ventilator Safety Notice Clouds Outlook; $230 Price Target Unchanged
Jefferies Analyst forecast on CH:RME
Matthew Taylor
Jefferies
Jefferies
CHF181.18
Hold
13.95%
Upside
Reiterated
07/10/26
Jefferies Issues a Hold Rating on Resmed (RMD)
Citi Analyst forecast on CH:RME
Laura Sutcliffe
Citi
Citi
CHF217.42→CHF189.23
Hold
19.01%
Upside
Downgraded
07/10/26
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD) and Eli Lilly & Co (NYSE: LLY)
Stifel Nicolaus Analyst forecast on CH:RME
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
CHF189.23
Hold
19.01%
Upside
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Meiragtx Holdings (NASDAQ: MGTX) and Resmed (NYSE: RMD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Resmed

3 Months
Brett FishbinKeyBanc
Success Rate
9/15 ratings generated profit
60%
Average Return
+2.96%
Copying Brett Fishbin's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.96% per trade.
1 Year
Lyanne HarrisonBank of America Securities
Success Rate
19/28 ratings generated profit
68%
Average Return
+10.13%
Copying Lyanne Harrison's trades and holding each position for 1 Year would result in 67.86% of your transactions generating a profit, with an average return of +10.13% per trade.
2 Years
Lyanne HarrisonBank of America Securities
Success Rate
17/28 ratings generated profit
61%
Average Return
+14.12%
Copying Lyanne Harrison's trades and holding each position for 2 Years would result in 60.71% of your transactions generating a profit, with an average return of +14.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RME Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
1
2
3
2
Buy
9
10
13
12
12
Hold
1
8
8
16
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
19
23
31
29
In the current month, RME has received 14 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. RME average Analyst price target in the past 3 months is 192.05.
Each month's total comprises the sum of three months' worth of ratings.

RME Financial Forecast

RME Earnings Forecast

Next quarter’s earnings estimate for RME is CHF2.19 with a range of CHF2.12 to CHF2.26. The previous quarter’s EPS was CHF2.40. RME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RME has Performed in-line its overall industry.
Next quarter’s earnings estimate for RME is CHF2.19 with a range of CHF2.12 to CHF2.26. The previous quarter’s EPS was CHF2.40. RME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RME has Performed in-line its overall industry.

RME Sales Forecast

Next quarter’s sales forecast for RME is CHF1.13B with a range of CHF1.11B to CHF1.16B. The previous quarter’s sales results were CHF1.19B. RME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RME has Performed in-line its overall industry.
Next quarter’s sales forecast for RME is CHF1.13B with a range of CHF1.11B to CHF1.16B. The previous quarter’s sales results were CHF1.19B. RME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RME has Performed in-line its overall industry.

RME Stock Forecast FAQ

What is CH:RME’s average 12-month price target, according to analysts?
Based on analyst ratings, Resmed’s 12-month average price target is 192.05.
    What is CH:RME’s upside potential, based on the analysts’ average price target?
    Resmed has 20.79% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Resmed a Buy, Sell or Hold?
          Resmed has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 11 hold ratings and 0 sell ratings.
            What is Resmed’s share price target?
            The average share price target for Resmed is 192.05. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF257.68 ,and the lowest forecast is CHF171.52. The average share price target represents 20.79% Increase from the current price of CHF159.
              What do analysts say about Resmed?
              Resmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of Resmed?
                To buy shares of CH:RME, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.